133 - Clesrovimab Efficacy through 6 Months during a Time of Changing SARS-CoV-2 Nonpharmaceutical Interventions (NPIs): Subgroup Analysis of the China Cohort in the Phase 2b/3 CLEVER Trial

Co-Author(s)

• MZ

  Mingfen Zhu, MSc

  MSD, China
  N/A, Beijing, China
• FS

  Fang Sun, MD

  MSD, China
  N/A, Beijing, China
• RW

  Rui Wang, MSc

  MSD, China
  N/A, Beijing, China
• DL

  Derong Liu, PhD

  MSD, China
  N/A, Beijing, China
• CC

  Chang Chen, PhD

  MSD, China
  N/A, Beijing, China
• RF

  Rong Fu, PhD

  MSD, China
  N/A, Beijing, China
• JL

  Jiahuang Lin, PhD

  MSD, China
  N/A, Beijing, China
• YL

  Yuanqiu Li, PhD (she/her/hers)

  Asso.Prin.Scientist, Epidemiology
  MSD, China
  N/A, Beijing, China
• QS

  Qiong Shou, PhD

  MSD, China
  N/A, Beijing, China
• 

  Andrea Guerra, MBBS (he/him/his)

  EMEA Regional Clinical Director
  MSD (UK) Limited, London, UK
  London, England, United Kingdom
• YZ

  Ying Zhang, PhD

  Merck & Co., Inc., Rahway, NJ, USA
  Rahway, New Jersey, United States
• RR

  Radha A. Railkar, PhD

  Merck & Co., Inc., Rahway, NJ, USA
  Rahway, New Jersey, United States

Rapid Fire Presenter(s)

• 

  Anushua Sinha, MD (she/her/hers)

  Director
  Merck & Co., Inc., Rahway, NJ, USA
  Rahway, NJ, United States

Co-Author(s)

• XL

  Xueyan Liao, PhD

  MSD, China
  N/A, Beijing, China